Shares of Genprex Inc (NASDAQ:GNPX) traded up 3.7% during mid-day trading on Monday . The company traded as high as $0.29 and last traded at $0.28, 276,351 shares were traded during trading. An increase of 107% from the average session volume of 133,604 shares. The stock had previously closed at $0.27.

The firm has a market capitalization of $4.28 million, a PE ratio of -0.32 and a beta of 1.14. The business has a 50 day moving average price of $0.43 and a 200-day moving average price of $0.94.

An institutional investor recently bought a new position in Genprex stock. Citadel Advisors LLC bought a new position in shares of Genprex Inc (NASDAQ:GNPX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned approximately 0.20% of Genprex at the end of the most recent quarter. Institutional investors own 12.62% of the company’s stock.

Genprex Company Profile (NASDAQ:GNPX)

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Further Reading: What is the LIBOR?

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.